GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invictus MD Strategies Corp (OTCPK:IVITF) » Definitions » EBITDA

Invictus MD Strategies (Invictus MD Strategies) EBITDA : $-24.87 Mil (TTM As of Oct. 2019)


View and export this data going back to 2015. Start your Free Trial

What is Invictus MD Strategies EBITDA?

Invictus MD Strategies's EBITDA for the three months ended in Oct. 2019 was $-6.04 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Oct. 2019 was $-24.87 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Invictus MD Strategies's EBITDA per Share for the three months ended in Oct. 2019 was $-0.05. Its EBITDA per share for the trailing twelve months (TTM) ended in Oct. 2019 was $-0.20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


Invictus MD Strategies EBITDA Historical Data

The historical data trend for Invictus MD Strategies's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invictus MD Strategies EBITDA Chart

Invictus MD Strategies Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19
EBITDA
-0.23 0.02 -4.59 -15.10 -25.12

Invictus MD Strategies Quarterly Data
Jan15 Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.65 -10.73 -2.74 -5.36 -6.04

Competitive Comparison of Invictus MD Strategies's EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Invictus MD Strategies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invictus MD Strategies's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invictus MD Strategies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Invictus MD Strategies's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Invictus MD Strategies's EBITDA for the fiscal year that ended in Jan. 2019 is calculated as

Invictus MD Strategies's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Jan. 2019, Invictus MD Strategies's EBITDA was $-25.12 Mil.

Invictus MD Strategies's EBITDA for the quarter that ended in Oct. 2019 is calculated as

Invictus MD Strategies's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Oct. 2019, Invictus MD Strategies's EBITDA was $-6.04 Mil.

EBITDA for the trailing twelve months (TTM) ended in Oct. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Invictus MD Strategies  (OTCPK:IVITF) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Invictus MD Strategies EBITDA Related Terms

Thank you for viewing the detailed overview of Invictus MD Strategies's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Invictus MD Strategies (Invictus MD Strategies) Business Description

Traded in Other Exchanges
N/A
Address
595 Burrard Street, 16th floor, Vancouver, BC, CAN, V7X 1J1
Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.

Invictus MD Strategies (Invictus MD Strategies) Headlines

From GuruFocus

INVICTUS CLOSES SALE OF FUTURE HARVEST DEVELOPMENT LTD.

By Marketwired Marketwired 10-17-2019

INVICTUS ANNOUNCES AB LABORATORIES INC. RECEIVES AMENDED LICENSE

By Marketwired Marketwired 09-11-2019

Invictus announces Annual General Meeting Results

By Marketwired Marketwired 07-25-2019

Invictus announces Closing of Non-Brokered Private Placement

By Marketwired Marketwired 07-09-2019

Invictus announces Annual General Meeting Date

By Marketwired Marketwired 06-20-2019

INVICTUS ANNOUNCES CHANGE TO BOARD

By GlobeNewswire GlobeNewswire 12-13-2019